Corcept Therapeutics (CORT) Cash from Investing Activities (2012 - 2026)

Corcept Therapeutics has reported Cash from Investing Activities for 15 years, with the latest figure at -$29.2 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 141.7% year-over-year to -$29.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$21.9 million (up 47.16% YoY) and the FY2025 annual result came in at $69.8 million, up 139.28% from the prior year.
• Cash from Investing Activities slipped to -$29.2 million in Q2 2026 per CORT's latest filing, from $4.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $207.5 million in Q1 2023 and troughed at -$109.6 million in Q3 2023.
• A 5-year average of -$8.7 million and a median of -$14.5 million in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 510.87% in 2023, down 2187.47% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$17.2 million in 2022, then jumped by 199.17% to $17.1 million in 2023, then slumped by 476.42% to -$64.4 million in 2024, then soared by 81.6% to -$11.8 million in 2025, then plunged by 146.91% to -$29.2 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$29.2 million, $4.5 million, and -$11.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.